Trade Mark Journal No.2025/022 30 May 2025
UK00004199916 7 May 2025 (42)
FABLE THERAPEUTICS
International priority date claimed: 12 November 2024
(United States of America)
(98849309)
- Class 42
- Product research, design, development and manufacturing services; pharmaceutical research, design, development and manufacturing services; Providing scientific, technical, and research consulting; Research and development of biological and pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; drug discovery services; pharmaceutical research and development services; Design and development of computer software for reading, transmitting, analysing and organising data; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information; software as a service (SAAS); platform as a service (PAAS); software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; artificial intelligence and machine learning software as a service (SAAS); Platforms for artificial intelligence as software as a service [SaaS]; Providing artificial intelligence computer programs on data networks; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; providing an online non-downloadable computer software platform for discovering proteins or drugs, forecasting potential uses of proteins or drug compounds and generating insights from screening and analyzing molecules, featuring software using artificial intelligence and machine learning; providing temporary use of non-downloadable computer software for discovering proteins or drugs, forecasting potential uses of proteins or drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; software as a service (SAAS) services featuring software for discovering proteins or drugs, forecasting potential uses of proteins or drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; providing an online non-downloadable computer software platform for analyzing molecular data; providing temporary use of non-downloadable computer software for generating or analyzing molecular data for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for generating or analyzing molecular data for biotechnology and pharmaceutical companies; preclinical drug discovery and development services used for identifying, designing, and optimizing chemical or biological compounds; pharmaceutical evaluation and preclinical evaluation of biological or chemical series and biological or chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing biological or chemical series and biological or chemical compounds via software using artificial intelligence and machine learning; providing an online searchable database in the fields of proteins or pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of proteins or pharmaceutical preparations, scientific development of new uses for proteins or pharmaceutical compounds, and scientific technical research; scientific research and development for forecasting the use of molecules as diagnostics, prognostics, or drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, diagnostics or prognostics; drug discovery services, namely, discovering novel molecules to develop into drug compounds; medical research and development in the field of biopharmaceuticals, diagnostics, prognostics, or protein engineering; information, consultancy and advisory services in relation to all of the above.
Fable Therapeutics, Inc.
Representative: CMS Cameron McKenna Nabarro Olswang LLP